Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1850 Versus Asfotase Alfa in Pediatric Participants With Hypophosphatasia (HPP)
NCT06079372Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Jul 2025
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of efzimfotase alfa in hypophosphatasia (HPP) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Treatment-emergent Adverse Events at Day 169. Started Apr 2024; status: active, not recruiting.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on NCT06079372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079372.